|
Session 22
Oral Abstracts
Recent Developments in Vaccines and Immune-based Therapies
Tuesday, 10 am-12:15 pm
Room: Room 710 |
| 10:00 am 83 |
Safety, Antiviral Effects, and Quantitative Measurement of Modified CD4 T Cells Trafficking to Gut Lymphoid Tissue in a Phase I/II Open-label Clinical Trial Evaluating Multiple Infusions of Lentiviral Vector-modified CD4 T Cells Expressing Long env Antisense
Ronald Collman*1, F Shaheen1, J Boyer1, G Binder1, L Zifchak1, F Aberra1, G McGarrity2, B Levine1, P Tebas1, and C June1
1Univ of Pennsylvania, Philadelphia, US and 2VIRxSYS Corp, Gaithersburg, MD, US |
| 10:15 am 84 |
Phenotypic Differences in Homing Receptor Expression on SIV-specific CD8+ T Cells Elicited by Intravenous vs Subcutaneous Inoculation with Single-cycle SIV
A Rahmberg1, W Neidermyer1, S Ng1, A Carville1, K Mansfield1, M Piatak2, J Lifson2, P Johnson1, and David Evans*1
1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US and 2SAIC, Frederick, MD, US and NCI, Frederick, MD, US |
| 10:30 am 85 |
Characterization of Adenovirus-specific T Cell Responses in AdHu5-based Vaccine Recipients
Natalie Hutnick*1, D Carnathan1, K Cox2, S Dubey2, D Casimiro2, H Ertl3, and M Betts1
1Univ of Pennsylvania, Philadelphia, US; 2Merck Res Labs, West Point, PA, US; and 3Wistar Inst, Philadelphia, PA, US |
| 10:45 am 86LB |
Vaccine-induced Targeting of Epitopes Associated with Spontaneous Control of HIV Viral Replication is Associated with Lower Set-point Viral Loads in HIV-Infected Participants from the STEP Trial
David Heckerman*1, N Frahm2,3, F Pereyra4, S Dubey5, D Geraghty3, J Carlson1, M Robertson5, J McElrath2,3, D Casimiro5, and B Walker4
1Microsoft Res, Los Angeles, CA, US; 2NIAID HIV Vaccine Trials Network, Seattle, WA, US; 3Fred Hutchinson Cancer Res Ctr, Univ of Washington, Seattle, US; 4Ragon Inst, Massachusetts Gen Hosp, Harvard Med Sch, Boston, US; and 5Merck Res Labs, Upper Gwynedd, PA, US |
| 11:00 am 87LB |
Characterization of a Potent HIV-specific CD4+ T Cell Response Induced by an Adjuvanted Protein HIV Vaccine in Seronegative Volunteers
L McNally1, E Van Braeckel2, P Bourguignon1, Marguerite Koutsoukos*1, F Clement2, M Janssens1, A Collard1, M-A Demoitié1, G Voss1, and G Leroux-Roels2
1GlaxoSmithKline Biologicals, Rixensart, Belgium and 2Ghent Univ and Hosp, Belgium |
| 11:15 am 88 |
Reduction of the Latent HIV-1 Reservoir in Resting CD4+ T Lymphocytes by High-dosage Intravenous Immunoglobulin Treatment Added to ART
A Lindkvist1, A Edén2, M Norström1,3, V Gonzalez1, S Nilsson4, B Svennerholm2, A Karlsson1,3, J Sandberg1, A Sönnerborg1, and Magnus Gisslén*2
1Karolinska Inst, Stockholm, Sweden; 2Sahlgrenska Univ Hosp, Univ of Gothenburg, Sweden; 3Swedish Inst for Infectious Disease Control, Solna; and 4Chalmers Univ of Tech, Gothenburg, Sweden |
| 11:30 am 89 |
Pharmacokinetic and Pharmacodynamic Parameters in HIV-1 Subjects Receiving Pegylated Interferon-a-2a Therapy: AIDS Clinical Trials Group Study 5192
David Asmuth*1, S Rosenkranz2, Y Cramer2, J Lertora3, C Rinaldo4, R Murphy5, R Schooley6, N Thielman7, X-D Li1, R Pollard1, and ACTG 5192
1Univ of California, Davis Sch of Med, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3NIH, Bethesda, MD, US; 4Univ of Pittsburgh, PA, US; 5Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; 6Univ of California, San Diego Sch of Med, US; and 7Duke Univ, Durham, NC, US |
| 11:45 am 90aLB |
Effect of Interleukin-2 on Clinical Outcomes in Patients with a CD4+ Cell Count of 300/mm3: Primary Results of the ESPRIT Study
Marcelo Losso*1, D Abrams2, and INSIGHT ESPRIT Study Group
1Hosp JM Ramos Mejia, Buenos Aires, Argentina and 2San Francisco Gen Hosp, Univ of California, San Francisco, US |
| 12:00 pm 90bLB |
Effect of Interleukin-2 on Clinical Outcomes in Patients with CD4+ Cell Count 50 to 299/mm3: Primary Results of the SILCAAT Study
Yves Levy and SILCAAT Sci Committee
Hosp Henri Mondor, France |
|
